Research use only · EU-warehoused · COA on every batch · HPLC ≥99% · Shipment 2–5 days
Log in Register
Home/ Catalogue/ Growth Hormone Secretagogues/ Tesamorelin
In stock
Tesamorelin

Tesamorelin

Lyophilised · ≥99% (HPLC) ·

Quantity Volume discounts auto-applied
Custom quantity
1

Supplied lyophilised. Reconstitution typically uses bacteriostatic water.

Independently third-party tested · COA on every batch · 48h EU dispatch
[01]

Overview

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH), stabilised by trans-3-hexenoic acid conjugation at the N-terminus to resist dipeptidyl peptidase IV degradation, and studied for its selective stimulation of pituitary growth hormone secretion. CAS 218949-48-5; molecular weight 5135.9 g/mol; belongs to the GHRH peptide class. Supplied lyophilised at ≥99% purity by HPLC. For laboratory research use only; not for human or veterinary use.

Stabilised at its N-terminus by a distinctive trans-3-hexenoyl cap, Tesamorelin is a synthetic analogue of human growth-hormone-releasing hormone (GHRH), a 44-residue peptide engineered for enhanced metabolic stability over the native hormone. It is among the most thoroughly characterised GHRH analogues in clinical endocrinology research, notably as a tool for studying visceral adiposity and the GH/IGF-1 axis.

A hormone fragment built to endure. Native GHRH is cleaved rapidly in circulation. By fusing a hexenoic-acid moiety to the full-length GRF(1-44) sequence, the molecule gains resistance to enzymatic degradation while retaining its ability to engage the GHRH receptor and drive pulsatile growth-hormone secretion. This stability is what allowed it to become the most extensively investigated analogue of its class in human metabolic studies (Wang et al., 2009; Tomlinson et al., 2006).

What the research explores. The peptide has anchored a large body of investigation into the endocrine control of fat distribution:

  • Visceral & hepatic fat — extensively studied for its effects on visceral adipose tissue and ectopic liver fat in HIV-associated lipodystrophy (Spooner et al., 2012; Dhillon et al., 2011).
  • Non-alcoholic fatty liver disease — clinical work examined changes in hepatic fat and liver health (Stanley et al., 2019).
  • Hepatic transcriptomics — studies delineated gene-expression and signalling pathways underlying the metabolic response (Fourman et al., 2020; Fourman et al., 2021).
  • Neurocognition & body composition — more recent trials assessed neurocognitive and compositional outcomes in research populations (Ellis et al., 2025; Russo et al., 2024).

These data arise from clinical and laboratory research; this listing makes no representation of therapeutic benefit outside those investigational contexts. Full citations are listed under the Scientific References tab.

Physicochemical profile. CAS 218949-48-5 · Molecular formula C₂₂₁H₃₆₆N₇₂O₆₇S · Molecular weight 5136 · Appearance: white lyophilized powder · Solubility: soluble in water.

Specification & quality. Each individually sealed vial contains 5 mg of Tesamorelin as a white lyophilized powder of ≥99% purity by HPLC. Every batch is third-party tested, with a Certificate of Analysis (COA) available. Store at −20 °C, protected from light and moisture. Shelf life: 24 months from the manufacture date.

This product is intended for laboratory research use only (RUO). It is not a drug, food, cosmetic, or dietary supplement, and is not for human or veterinary use, ingestion, or diagnostic application. Handling is restricted to qualified research professionals operating in an appropriately equipped laboratory.

Supplied for in-vitro laboratory research use only (RUO). Not a drug, food or supplement; not for human or veterinary use.

[04]

Quality & COA

Certificate of Analysis
Lot-specific COA with every order

Certificate of Analysis — lot-specific COA ships with every order and is available on request.

Each lot is tested by an independent third-party laboratory for identity (mass spectrometry) and purity (HPLC). The Certificate of Analysis for your specific batch ships with the order and is available on request — no house data, no exceptions.

HPLC purity
≥99% (HPLC)
Method
HPLC + MS
Endotoxin
Reported
[02]

Data Sheet

CAS number218949-48-5
Molecular formulaC₂₂₁H₃₆₆N₇₂O₆₇S
Molecular weight5136
Sequencetrans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂
Purity≥99% (HPLC)
Physical formWhite lyophilized powder
Quantity5mg/vial
SolubilitySoluble in water
StorageStore at -20°C, protect from light
Shelf life24 months from manufacture date
OriginEU · Slovakia
ClassificationResearch use only
[03]

Scientific References

01 Badran AS, Helal A, Shata KS, Ayesh H. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. PMID: 41545261. doi:10.1016/j.orcp.2026.01.002. PubMed 02 . Tesamorelin. . 2012. PMID: 31644039. PubMed 03 Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012;46(2):240-7. PMID: 22298602. doi:10.1345/aph.1Q629. PubMed 04 Dhillon S. Spotlight on tesamorelin in HIV-associated lipodystrophy. BioDrugs. 2011;25(6):405-8. PMID: 22050344. doi:10.2165/11208290-000000000-00000. PubMed 05 Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-91. PMID: 21668043. doi:10.2165/11202240-000000000-00000. PubMed 06 Wang Y, Tomlinson B. Tesamorelin, a human growth hormone releasing factor analogue. Expert Opin Investig Drugs. 2009;18(3):303-10. PMID: 19243281. doi:10.1517/13543780802707658. PubMed 07 Tomlinson B. Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor. Curr Opin Investig Drugs. 2006;7(10):936-45. PMID: 17086939. PubMed 08 Beach R, Tims-Cook Z, McGary CS, Thote T. Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists. Clin Infect Dis. 2026;82(Supplement_4):S87-S91. PMID: 42139091. doi:10.1093/cid/ciag121. PubMed 09 Ellis RJ, Vaida F, Hu K, Dube M, Henry B, Chow F, et al. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. J Infect Dis. 2025;231(5):1230-1238. PMID: 39813152. doi:10.1093/infdis/jiaf012. PubMed 10 Russo SC, Ockene MW, Arpante AK, Johnson JE, Lee H, Toribio M, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12):1758-1764. PMID: 38905488. doi:10.1097/QAD.0000000000003965. PubMed 11 Rahman F, McLaughlin T, Mesquita P, Morin J, Potvin D, De Chantal M, et al. Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. J Clin Transl Sci. 2023;7(1):e40. PMID: 36845310. doi:10.1017/cts.2022.515. PubMed 12 Lake JE, La K, Erlandson KM, Adrian S, Yenokyan G, Scherzinger A, et al. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS. 2021;35(9):1395-1402. PMID: 33756511. doi:10.1097/QAD.0000000000002897. PubMed 13 Fourman LT, Stanley TL, Billingsley JM, Sui SJH, Feldpausch MN, Boutin A, et al. Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Sci Rep. 2021;11(1):10485. PMID: 34006921. doi:10.1038/s41598-021-89966-y. PubMed 14 Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020;5(16). PMID: 32701508. doi:10.1172/jci.insight.140134. PubMed 15 Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PMID: 31611038. doi:10.1016/S2352-3018(19)30338-8. PubMed

References are illustrative of the research literature surrounding this compound. All claims relate to in-vitro and animal models only.

[05]

FAQ

Tesamorelin is a synthetic analogue of human growth-hormone-releasing hormone (GHRH), a 44-residue peptide stabilized at its N-terminus by a distinctive trans-3-hexenoyl cap that improves its metabolic stability over the native hormone. Condor Research supplies it as a 5 mg lyophilized vial, third-party tested to ≥99% purity by HPLC, strictly for in-vitro research use.

Length and stabilization differ. Sermorelin is the minimal 29-residue GRF(1-29) fragment with no added protection, whereas Tesamorelin is a longer 44-residue GHRH analogue carrying a trans-3-hexenoyl cap that resists enzymatic breakdown. Both are GHRH-analogue research peptides, but Tesamorelin is engineered for greater metabolic stability. Each is sold as Research Use Only material.

The trans-3-hexenoyl cap on Tesamorelin's N-terminus shields it from rapid enzymatic degradation, extending its stability relative to the unmodified GRF(1-29) sequence of Sermorelin. This makes Tesamorelin a longer, more stable GHRH analogue, while Sermorelin represents the native minimal active core. Both are studied as in-vitro reference peptides.

Both are stabilized GHRH analogues using different approaches. Tesamorelin is a 44-residue peptide stabilized by a trans-3-hexenoyl cap; CJC-1295 (no DAC), or Modified GRF (1-29), is a 29-residue fragment stabilized by amino-acid substitutions. They are distinct research molecules at the GHRH-receptor pathway. Both are supplied strictly for in-vitro laboratory use.

They act at opposite points of growth-hormone biology. Tesamorelin is a GHRH analogue, a secretagogue-type molecule modeled on the hormone that signals upstream of GH. AOD-9604 is instead a fragment of the GH molecule itself (residues 177-191), studied as a lipolytic-domain peptide. Both are offered as Research Use Only reference compounds.

All three are GHRH-receptor analogues differing in length and stabilization: Sermorelin is the native 29-residue GRF(1-29); CJC-1295 no DAC is the substitution-stabilized Modified GRF (1-29); Tesamorelin is the 44-residue, hexenoyl-capped analogue. Selection depends on your in-vitro model. Condor Research supplies them as research materials only and gives no use protocols — research design is the investigator's.

Each lot is tested by an independent third-party laboratory, with identity and purity confirmed by HPLC and mass spec, and ships with a batch-specific Certificate of Analysis certifying ≥99% purity. The listed sequence and molecular weight (5136) correspond to hexenoyl-capped Tesamorelin. To request the current lot COA, email info@condorresearch.com.

Tesamorelin is a water-soluble lyophilized powder, dissolved in a compatible aqueous diluent for in-vitro preparation, with volume chosen to reach the target analytical concentration from the 5 mg vial. Store the sealed vial at -20°C, protected from light (24-month shelf life). This is analytical preparation only; no human or veterinary dosing guidance is provided.

No — Tesamorelin is supplied strictly as a Research Use Only (in vitro) reference material: not a medicine, supplement or medical device, and not for human or veterinary administration or consumption. Sales are restricted to professionals and institutions aged 18+. Buyers are responsible for confirming the legality of import in their own country.

[06]

Reviews

Leave a review
Earn 250 points for a verified review (account required).
4.7
99 verified reviews
5
78%
4
16%
3
4%
2
1%
1
1%
Apr 2026
Exactly what research needs

No marketing fluff — just characterised material with paperwork. The data sheet and CAS matched our records precisely.

J. Meijer · Biotech R&D · NL Verified purchase
Mar 2026
High purity, clear labelling

Lyophilised cake was uniform and dissolved fully. Would appreciate a digital COA portal, but the PDF on request worked fine.

Dr. A. Bianchi · University · IT Verified purchase
Mar 2026
Trustworthy supplier

Identity by MS confirmed in our facility. Communication around storage and handling was precise and professional.

K. Wójcik · Research group · PL Verified purchase
Feb 2026
Reference-grade consistency

Reconstitution was clean with no visible particulates. The lot-specific COA matched the assay we ran in-house — purity is exactly as stated.

Dr. M. Hartmann · Research lab · DE Verified purchase
Jan 2026
COA matched our own HPLC

We verify every incoming compound by HPLC; this batch came back within tolerance of the certificate. Dispatch from the EU warehouse was quick.

L. Fischer · University group · AT Verified purchase

Related compounds